Video Insights

Roundtable: Focus on Bispecifics in Myeloma
Melissa BadamoMyelodysplastic Syndromes | April 16, 2024
The average rate of progression for CHIP to MDS or AML is about 1% per year, Dr. Patel explained.
View More
Kenneth Anderson, MDMyeloma | April 11, 2024
The “real revolution” in myeloma is in the immune therapies, Dr. Anderson said, such as bispecific T-cell engagers and ...
Edward Cliff, MDBlood Cancer Talks | April 11, 2024
Dr Cliff describes an analysis of oncology drugs that were approved via the FDA Accelerated Approval Program over 10 years.
Shaikha Alqahtani, MDAcute Myeloid Leukemia | April 10, 2024
Around 45% of patients had a complete response after cladribine, and 31% proceeded to transplant.
Melissa BadamoAcute Myeloid Leukemia | April 9, 2024
The researchers found that CALM-AF10 leukemia cells grow slower after the SIX1 knockdown.
Leah SherwoodAcute Myeloid Leukemia | April 16, 2024
Claudio Cerchione, MD, PhD, describes his presentation from AACR 2024 on a emavusertib triplet in patients with AML.
Melissa BadamoMyeloma | April 8, 2024
The overall response rate was 71%, and the most common side effects were CRS, neutropenia, and anemia.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | March 26, 2024
Dr. Chadi Nabhan brings "The HemOnc Pulse" live to Chicago May 3-4.
Leah SherwoodMyelodysplastic Syndromes | March 25, 2024
The Leukemia and Lymphoma Society's CMML Initiative hopes for dedicated CMML trials and CMML-directed therapies.
Tanya Siddiqi, MDChronic Lymphocytic Leukemia | March 29, 2024
Dr. Siddiqi shares data from the phase I/II TRANSCEND CLL 004 trial on liso-cel in patients with relapsed or refractory CLL.
Melissa BadamoMyelodysplastic Syndromes | March 22, 2024
The case study included four patients with CMML who had KRAS mutations and a multitude of autoimmune diseases.
Melissa BadamoMyeloma | March 13, 2024
For Dr. Banerjee, this month is a call to action to mitigate global disparities in myeloma treatment.
Melissa BadamoChronic Lymphocytic Leukemia | March 11, 2024
The researchers developed CAR T-cells that target and eliminate mutated CLL cells while sparing healthy B-cells.
Nicolaus Kröger, MDMyelofibrosis | March 4, 2024
Nicolaus Kröger, MD, discusses a study on GVHD and its impact on relapse in patients with myelofibrosis undergoing HSCT.
Prithviraj Bose, MDMyelofibrosis | February 29, 2024
Myelofibrosis, a rare blood cancer, affects four to six per 100,000 individuals in the United States.
Richard Newcomb, MDTransplantation & Cellular Therapy | February 26, 2024
Approach-oriented coping was associated with higher quality of life and lower symptoms of depression and anxiety.
Shambavi Richard, MDTransplantation & Cellular Therapy | February 20, 2024
The mandate could affect moving CAR-T therapies into earlier lines of therapy for multiple myeloma.
Pieter Sonneveld, MD, PhDMyeloma | February 16, 2024
The addition of daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance therapy improved PFS.
Justin Taylor, MDChronic Lymphocytic Leukemia | February 14, 2024
The study defined mutations that develop resistance to BTK inhibitors and evaluated the BTK degrader NX-2127 in CLL.
Shambavi Richard, MDVideo Insights | February 8, 2024
The scales are shifting in the STEM fields as more women step into positions of responsibility, leadership, and influence.
Mariia Mikhaleva, MDVideo Insights | February 2, 2024
Mariia Mikhaleva MD, a research fellow at the Dana-Farber Cancer Institute, describes how it felt to receive the award.
Mariia Mikhaleva, MDChronic Lymphocytic Leukemia | January 26, 2024
The presence of two or more mutations are associated with high-risk cell features.
Chadi Nabhan, MD, MBA, FACPTransplantation & Cellular Therapy | January 26, 2024
The latest HemOnc Pulse episode looks at the science behind the statement from the FDA on the risk of CAR-T therapies.
Sanjay Patel, MDVideo Insights | January 19, 2024
Sanjay Patel, MD, discusses a study on spatial mapping of human hematopoiesis using bone marrow tissue.
Paula Rodríguez Otero, MDMyeloma | February 15, 2024
Paula Rodríguez Otero, MD, described an updated analysis of the KarMMa-3 trial presented at the 65th ASH Annual Meeting.
Dwight Macero, PA-C, MSMyeloma | January 8, 2024
Physician Assistant Dwight Macero, one of the clinical consultants on the survey, offers his thoughts on the results.
Leyla Shune, MDMyeloma | January 5, 2024
Leyla Shune, MD, discusses the import of promising data for ide-cel in multiple myeloma presented at the 2023 ASH Meeting.
Ajai Chari, MDTransplantation & Cellular Therapy | January 24, 2024
The investigation is "likely not going to change the risk-benefit profile of these approved products," Dr. Chari said.
Claire Harrison, MD, FRCP, FRCPathMyelofibrosis | February 29, 2024
FREEDOM2 is a phase III study comparing fedratinib with best available therapy as a second-line treatment for myelofibrosis.
Rafael Fonseca, MDMyeloma | January 4, 2024
Dr. Fonseca, of the Mayo Clinic, spoke with Blood Cancers Today about idecabtagene vicleucel in myeloma treatment.

Knowledge Hubs

Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
Editorial Board